December 12, 2016 11:16 AM EST
Startups

Pfiz­er bankrolls an on­colyt­ics biotech up­start with an eye on a fu­ture buy­out

John Carroll

Editor & Founder

Pfiz­er is bankrolling a new on­colyt­ic virus start­up, tak­ing a 50% stake in the can­cer drug out­fit while hold­ing an op­tion to buy it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Wal­greens in talks to sell to pri­vate eq­ui­ty — re­port

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times